Unique partnership with Medtronic will enable continuous glucose monitoring (CGM) sensors based on Abbott's FreeStyle Libre sensing technology to integrate with Medtronic's insulin delivery systems Abbott now has partnerships with four of the largest companies that develop automated insulin delivery systems – offering more choices to people around the world to benefit from connectivity with Libre technology ABBOTT PARK, Ill., Aug. 7, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced a unique global ...

There are blue-chip bargains paying large and growing dividends in the healthcare space.Dividend growth investing is an excellent strategy for any long-term investor. It involves buying and holding companies that pay and raise their dividends year after year. Investors benefit from dividends; you can reinvest them to buy more shares or pay living expenses. Additionally, companies must grow and responsibly manage their money to afford an ever-increasing obligation like a growing dividend. It's a back-door li ...

Abbott (ABT) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ABT broke through the 200-day moving average, which suggests a long-term bullish trend.The 200-day simple moving average helps traders and analysts determine overall long-term market trends for stocks, commodities, indexes, and other financial instruments. The indicator moves higher or lower along with longer-term price moves, serving as a support or resistance level.ABT has ralli ...

Johnson & Johnson Overview - Johnson & Johnson is a top healthcare company focusing on innovative medicines and medical devices after spinning off its consumer health business [1] - The company expects a growth rate of 5-7% over the years but faces challenges such as talc lawsuits and the upcoming loss of exclusivity for its top-selling drug Stelara [1] Abbott Laboratories Overview - Abbott Laboratories has a more diverse business model compared to Johnson & Johnson, with revenue streams from nutrition, diagnostics, established pharmaceuticals, and medical devices [2] - Sales grew by over 3% to $20.3 billion in the first six months of the year, despite a 12% decline in diagnostics due to reduced COVID-19 testing sales [2] - Medical device revenue grew by over 12%, accounting for 45% of total revenue, making it the fastest-growing segment [4] Growth Potential of Abbott Laboratories - Abbott Laboratories faces fewer legal challenges compared to Johnson & Johnson, which is dealing with tens of thousands of lawsuits [3] - The company's medical device business, particularly in diabetes care, shows strong growth potential with FreeStyle Libre CGM devices generating $3.2 billion in revenue, an 18% increase from the previous year [4] - Recent FDA clearance for two new CGM devices, Libre Rio and Lingo, expands the market beyond insulin-dependent diabetics, potentially accelerating growth [5] - The CGM market is projected to nearly double from $11.6 billion in 2024 to $21.3 billion by 2029, with Abbott Laboratories positioned as a key player [5] Investment Recommendation - Abbott Laboratories is considered a better growth investment compared to Johnson & Johnson due to its lower risk profile and strong growth potential in the medical device sector [6][7]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-2189 ABBOTT LABORATORIES An Illinois Corporation I.R.S. Employer Identification No. 36-0698440 100 Abbott Park Road ...

MedTech Industry Overview - The MedTech industry reached a valuation of $503.2 billion in 2022 and is projected to grow to $776.5 billion by 2033, implying a CAGR of 4.4% [1] - Key growth areas over the next five years include cardiovascular health, digital healthcare, and robotics [1] - Rising global prevalence of chronic conditions like diabetes, cardiovascular disease, and obesity is driving MedTech relevance [1] Johnson & Johnson (JNJ) - J&J operates in pharmaceuticals and medical devices, covering orthopedics, surgery, interventional solutions, and vision care [3] - The company posted an average EPS of $2.62 in the past year, beating consensus estimates by 3.28% [3] - JNJ stock trades at 4.5X trailing-year sales, with analysts projecting EPS of $10.71 and revenue of $91.11 billion by fiscal 2025 [4] Abbott Laboratories (ABT) - Abbott offers solutions in diagnostics, nutrition, pharmaceuticals, and medical devices, with a strong presence in cardiovascular and diabetes care [5][6] - The company achieved an average EPS of $1.11 in the past year, slightly beating consensus estimates by 2.6% [6] - ABT stock trades at 4.5X sales, with analysts forecasting 5% EPS growth to $4.66 and 4.1% revenue growth to $41.74 billion by year-end [7] Edwards Lifesciences (EW) - Edwards specializes in structural heart diseases, focusing on heart valve replacement technologies and critical care monitoring systems [8] - The company posted an average EPS of 65 cents, beating consensus estimates by 1 cent [8] - EW stock trades at 6.72X trailing-year sales, with analysts projecting 8% EPS growth to $2.70 and 6.4% revenue growth to $6.39 billion by year-end [9] Glaukos (GKOS) - Glaukos develops devices and therapeutics for glaucoma, corneal disorders, and retinal diseases, pioneering micro-invasive glaucoma surgery [10] - The company reported a loss per share of 60 cents in the past year, worse than the anticipated 56-cent loss [10] - GKOS stock trades at 18X sales, with analysts projecting significant revenue growth to $451.62 million by fiscal 2025 [10] Inari Medical (NARI) - Inari develops minimally invasive catheter-based devices for venous diseases, including its LimFlow product for chronic limb-threatening ischemia [11] - The company posted an average loss per share of 5 cents, better than the expected 8-cent loss [11] - NARI stock trades at 5.89X sales, with analysts forecasting 21.3% revenue growth to $598.72 million by 2024 [12] iRhythm Technologies (IRTC) - iRhythm specializes in ambulatory cardiac monitoring services, known for its Zio Monitor patch for arrhythmia detection [13] - The company reported a loss per share of $1, worse than the expected 74-cent loss [13] - IRTC stock trades at 5.3X sales, with analysts projecting 18.4% revenue growth to $583.5 million by fiscal 2024 [14] SI-Bone (SIBN) - SI-Bone offers minimally invasive surgical implants for sacroiliac joint dysfunction [15] - The company posted an average loss per share of 27 cents, better than the expected 33-cent loss [15] - SIBN stock trades at 4.19X sales, with analysts forecasting 18.8% revenue growth to $165.05 million by year-end and further growth to $191.54 million in the following year [16]

Parradee Kietsirikul/iStock via Getty Images 2024 Review The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) ended the first half of 2024 on a sour note, falling by 1.4% during the month of June. Despite the lackluster finish, NOBL was up 1.95% during the first half of this year. To make matters worse, the SPDR S&P 500 Trust ETF (SPY) added 3.53% to its return in June and finished the first half of the year up 15.23%. The second half of the year started out just the way the first half finished, with T ...

Key TakeawaysA jury in St. Louis ruled on Friday that Abbott Laboratories must pay $495 million in compensation and damages in a lawsuit involving the company's premature infant formula.Abbott was sued by an Illinois woman whose daughter contracted necrotizing enterocolitis after being given the formula in the hospital.The company has denied its product is unsafe.Abbott shares fell as much as 5% in early trading Monday. Shares of Abbott Laboratories (ABT) came under pressure Monday after a jury in St. Louis ...

Abbott Laboratories (NYSE:ABT)) is off 3.6% to trade at $101.44 this morning, suffering a drop after its premature infant formula trial ended in the company needing to pay $495 million in damages to those impacted by a possible increase in bowel disease. An Abbott spokesperson stands against the verdict, adamant the company will appeal.Alongside today's drop, ABT also succumbed to pressure at its 100-day moving average, a trendline that's sat overhead since early April. The medical equipment stock remains i ...

Abbott Labs (NYSE:ABT) stock is falling more than 4% after a St. Louis jury found its premature infant baby formula responsible for a potentially fatal bowel disease.As of this writing, ABT stock is trading around the $100 mark. The market capitalization of Abbott is $175 billion on estimated sales of $38.4 billion for 2024. A Formula for Legal TroubleThe case was filed on behalf of Margo Gill and her daughter, who developed necrotizing enterocolitis (NEC) and suffered severe brain damage after being given ...